Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-10-18
2011-12-20
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S209100, C424S205100, C424S206100
Reexamination Certificate
active
08080255
ABSTRACT:
The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
REFERENCES:
patent: 6649372 (2003-11-01), Palese et al.
patent: 7556940 (2009-07-01), Galarza et al.
patent: 2003/0035814 (2003-02-01), Kawaoka et al.
patent: 2005/0009008 (2005-01-01), Robinson et al.
patent: WO 96/37624 (1996-11-01), None
patent: WO 02/00085 (2002-01-01), None
patent: WO 02/00885 (2002-01-01), None
Li et al. Journal of Infectious Dis. 1999 vol. 179, pp. 1132-1138.
NCBI accession # CY014173 (available Aug. 30, 2006).
Wood, J. M., et al., Preparation of Vaccines Against H5N1 Influenza, Vaccine, vol. 20, Supplement 2, May 15, 2002, pp. S84-S87.
Bender, C., et al., Characterization of the Surface Proteins of Influenza A (H5N1) Viruses Isolated from Humans in 1997-1998, Virology, vol. 254, Issue 1, Feb. 1, 1999, pp. 115-123 abstract and Figure 1 and Table 1.
Chen, H., et al., The Evolution of H5N1 Influenza Viruses in Ducks in Southern China. Proc Natl Acad Sci USA 2004 vol. 101, No. 28, pp. 10452-10457, see sequence AY585375.
Saito, T., et al., “Characterization of a human H9N2 influenza virus isolated in Hong Kong,”Vaccine20(1-2):125-133 (2001).
Gupta, R.K., et al., “Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens,”Vaccine14(3):219-225 (1996).
Ali, Ayub et al., “Influenza Virus Assembly: Effect of Influenza Virus Glycoproteins on the Membrane Association of M1 Protein”,Journal of Virology, Sep. 2000, vol. 74, No. 18, pp. 8709-8719.
Bullido, Rosario et al., “Several Protein Regions Contribute to Determine the Nuclear and Cytoplasmic Localization of the Influenza A Virus Nucleoprotein”,Journal of General Virology, 2000, 81, pp. 135-142.
Castrucci, Maria R. et al., “Reverse Genetics System for Generation of an Influenza A Virus Mutant Containing a Deletion of the Carboxyl-Terminal Residue of M2 Protein”,Journal of Virology, May 1995, vol. 69, No. 5, pp. 2725-2728.
Elster, Christine et al., “Influenza Virus MI Protein Binds to RNA Through Its Nuclear Localization Signal”,Journal of General Virology, 1997, 78, pp. 1589-1956.
Fodor, Ervin et al., “Rescue of Influenza A Virus from Recombinant DNA”,Journal of Virology, Nov. 1999, vol. 73, No. 11, pp. 9679-9682.
Gómez-Puertas, Paulino et al., “Efficient Formation of Influenza Virus-Like Particles: Dependence on the Expression Levels of Viral Proteins”,Journal of General Virology, 1999, 80 pp. 1635-1645.
Gómez-Puertas, Paulino et al., “Influenza Virus Matrix Protein is the Major Driving Force in Virus Budding”,Journal of Virology, Dec. 2000, vol. 74, No. 24, pp. 11538-11547.
Hoffmann, Erich et al., “A DNA Transfection System for Generation of Influenza A Virus from Eight Plasmids”,PNAS, May 23, 2000, vol. 97, No. 11, pp. 6108-6113.
Kuroda, Kazumichi et al., “Expression of the Influenza virus Haemagglutinin in Insect Cells by a Baculovirus Vector”,The EMBO Journal, 1986, vol. 5 No. 6, pp. 1359-1365.
Li, Shengqiang et al., “Chimeric Influenza Virus Induces Neutralizing Antibodies and Cytotoxic T Cells Against Human Immunodeficiency Virus Type 1”,Journal of Virology, Nov. 1993, vol. 67, No. 11, pp. 6659-6666.
Lyles, Douglas S. et al. “Subunit Interactions of Vesicular Stomatitis Virus Envelope Glycoprotein Stablilized by Binding to Viral Matrix Protein”,Journal of Virology, Jan. 1992, vol. 66 No. 1, pp. 349-358.
Mena, Ignacio et al., “Rescue of a Synthetic Chloramphenicol Acetyltransferase RNA into Influenza Virus-Like Particles Obtained from Recombinant Plasmids”,Journal of Virology. Aug. 1996, vol. 70, No. 8, pp. 5016-5024.
Neumann, Gabriele et al., “Generation of Influenza A Viruses Entirely from Cloned cDNAs”,Proc. Natl. Acad. Sci USA, Aug. 1999, vol. 96, pp. 935-9350.
Pattnaik, Asit K. et al., “Formation of Influenza Virus particles Lacking Hemagglutinin on the Viral Envelope”,Journal of Virology, Dec. 1986, vol. 60, No. 3, pp. 994-1001.
Pleschka, Stephan et al., “A Plasmid-Based Reverse Genetics System for Influenza A Virus”,Journal of Virology, Jun. 1996, vol. 70, No. 6, pp. 4188-4192.
St. Angelo, Carol et al., “Two of the Three Influenza Viral Polymerase Proteins Expressed by Using Baculovirus Vectors Form a Complex in Insect Cells”,Journal of Virology, Feb. 1987, vol. 61, No. 2, pp. 361-365.
Tobita, Kiyotake et al., “Spontaneous Excretion of Virus from MDCK Cells Persistently Infected with Influenza Virus A/PR/8/34”,Journal of General Virology, 1997, 78, pp. 563-566.
Yasuda, Jim et al., “Growth Control of Influenza A Virus by MI Protein: Analysis of Transfectant Viruses Carrying the Chimeric M Gene”,Journal of Virology, Dec. 1994, vol. 68, No. 12, pp. 8141-8146.
Ye, Zhiping et al., “Nucleus-Targeting Domain of the Matrix Protein (MI) of Influenza Virus”,Journal of Virology, Mar. 1995, vol. 69, No. 3, pp. 1964-1970.
Zhao, Hongxing et al., “The MI and NP Proteins of Influenza A Virus Form Homo- but not Heterooligomeric Complexes when Coexpressed in BHK-21 Cells”,Journal of General Virology, 1998, 79, pp. 2435-2446.
Crowther, R.A. , et al., “Three-Dimensional Structure of Hepatitis B. Virus Core Particles Determined by Electron Cryomicroscopy,”Cell, vol. 77, pp. 943-950, Jun. 17, 1994.
Murphy, Brian R. and Robert G. Webster,Orthomyxoviruses, Fields Virology, Third Edition, vol. 1, pp. 1397-1445, 1996.
Zhou, Xianzehng et al., “Generation of Cytotoxic and Humoral Immune-Responses by Non-replicative Recombinant Semlike Forest Virus,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 3009-3013, Mar. 1995.
Treanor, John J. et al., “Evaluation of a Recombinant Hemagglutinin Expressed in Insect Cells as an Influenza Vaccine in Young an Elderly Adults,”The Journal of Infectious Diseases, vol. 173, pp. 1467-1470, 1996.
Lakey, et al., “Recombinant Baculovirus Influenza A Hemagglutinin Vaccines are Well Tolerated and Immunogenic in Healthy Adults, Concise Communications”JID1996; 174 (October) pp. 838.841.
Johansson, Bert E. , “Immunization with Influenza A Virus Hemagglutinin and Neuraminidase Produced in Recobinant Baculovirus Results in a Balanced and Broadened Immune Response Superior to Conventional Vaccine,”Vaccine17, pp. 2073-2080 (1999).
Pushko, Peter et al., “Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization Against Heterologous Pathogens in Vivo,”Virology, vol. 239, pp. 389-401 (1997).
Ulmer, Jeffrey B. et al., “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein,”Science, vol. 259, Mar. 19, 1993, pp. 1745-1749.
Berglund, Peter et al., “Immunization with Recombinant Semlike Forest Virus Induces Protection Against Influenza Challenge in Mice,”Vaccine17 (1999) pp. 497-507.
Cox, John C. and Ann R. Coulter, “Adjuvants—A Classification and Review of Their Modes of Action,”Vaccine, vol. 15, No. 3, pp. 248-256, 1997.
Crawford, John et al., “Baculovirus-Derived Hemagglutinin Vaccines Protect Against Lethal Influenza Infections by Avian H5 and H7 Subtypes,”Vaccine17 (1999), pp. 2265-2274.
Latham, Theresa and Jose M. Galarza, “Formation of Wild-Type and Chimeric Influenza Virus-Like Particles Fol
Bright Rick
Mahmood Kutub
Pushko Peter
Smith Gale
Zhang Jinyou
Cooley LLP
Hill Myron
Mosher Mary E
Novavax Inc.
LandOfFree
Functional influenza virus like particles (VLPs) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Functional influenza virus like particles (VLPs), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Functional influenza virus like particles (VLPs) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264059